Gradientech presented QuickMIC® performance data at the 17th National Microbiology Conference in Romania
The diagnostics company Gradientech announces the presentation of newly published outstanding performance data on QuickMIC® at the 17th National Conference of Microbiology and Epidemiology in Iași, Romania, 7-9 November 2024.
The national conference in Iași brought together experts in infectious diseases and clinical microbiology from across Romania to discuss urgent public health challenges. The sessions addressed various topics, including innovative diagnostics and infection prevention strategies.
The QuickMIC® system was showcased by Biomedica Medizinprodukte GmbH, Gradientech’s appointed distributor for Austria, Switzerland, and Central Eastern Europe. Dr. Anna Olsson, Clinical Study Manager at Gradientech delivered a well-received presentation entitled Implementation of Rapid AST Facilitating Same-Shift Sepsis Diagnostics Using Precise and Accurate MIC Values. "We are proud of our close collaboration with Biomedica to showcase how the QuickMIC system can function as an essential tool for ultra-rapid antibiotic susceptibility testing and significantly contribute to the everyday work of clinical microbiologists in sepsis diagnostics and the wellbeing of their patients" says Anna Olsson.
“It’s very encouraging to see the great interest from the Romanian market where the QuickMIC system with its ultra-rapid speed, small instrument size, and unique precision, can make a real difference in the management of critically ill patients,” says Ileana Anghel, Country Manager at Biomedica Medizinprodukte Romania SRL.
The ultra-rapid and precise antibiotic susceptibility testing results of QuickMIC® contribute to timely and effective management of sepsis patients, helping clinicians make faster antibiotic treatment decisions. Its modular design offers affordable scaling possibilities, making QuickMIC suitable for both small and large hospital laboratories. QuickMIC and its gram-negative panel are CE marked and commercially available in Europe but not yet available for sale in the United States.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.
